Carotid Stent, AAA Market Entry: Boston Scientific Moves On Earn-Outs
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific intends to acquire carotid stent manufacturer EndoTex by year-end, following an anticipated FDA approval of NexStent
You may also be interested in...
Boston Scientific Spins Out TriVascular AAA Biz To Investors For $30 Mil.
Boston Scientific's reversal of its April 2005 acquisition of endovascular aortic aneurysm repair device developer TriVascular puts the newly independent entity back in the hands of its original management team in exchange for $30 million and a minority equity stake
Boston Scientific Spins Out TriVascular AAA Biz To Investors For $30 Mil.
Boston Scientific's reversal of its April 2005 acquisition of endovascular aortic aneurysm repair device developer TriVascular puts the newly independent entity back in the hands of its original management team in exchange for $30 million and a minority equity stake
FDA Hands Boston Scientific Warning Letter For Clinical Trial Violations
A recent bioresearch monitoring 1warning letter to Boston Scientific, sent Aug. 30, is unrelated to an outstanding corporate-wide letter issued to the firm in 2006 - but the two letters, taken together, could make life harder for the company